Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1

Tissue eosinophilia prevention represents one of the primary targets to new anti-allergic therapies. As lipoxin A4 (LXA4) and aspirin-triggered 15-epi-LXA4 (ATL) are emerging as endogenous “stop signals” produced in distinct pathologies including some eosinophil-related pulmonary disorders, we evaluated the impact of in situ LXA4/ATL metabolically stable analogues on allergen-induced eosinophilic pleurisy in sensitized rats. LXA4/ATL analogues dramatically blocked allergic pleural eosinophil influx, while concurrently increasing circulating eosinophilia, inhibiting the earlier edema and neutrophilia associated with allergic reaction. The mechanisms underlying this LXA4/ATL-driven allergic eosinophilia blockade was independent of mast cell degranulation and involved LXA4/ATL inhibition of both IL-5 and eotaxin generation, as well as platelet activating factor action. These findings reveal LXA4/ATL as a novel class of endogenous anti-allergic mediators, capable of preventing local eosinophilia.

[1]  C. Clish,et al.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Serhan,et al.  Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1α–initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine–Chemokine Axis , 1999, The Journal of experimental medicine.

[3]  C. Serhan,et al.  LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively downregulate PMN azurophilic degranulation. , 1999, American journal of physiology. Cell physiology.

[4]  M. Martins,et al.  Systemic and local dexamethasone treatments prevent allergic eosinophilia in rats via distinct mechanisms. , 1999, European journal of pharmacology.

[5]  T. Takano,et al.  Aspirin-triggered 15-epi-lipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation. Receptors and pathways. , 1999, Advances in experimental medicine and biology.

[6]  C. Serhan,et al.  Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs. , 1998, The Journal of clinical investigation.

[7]  C. Serhan,et al.  Identification of a Human Enterocyte Lipoxin A4 Receptor That Is Regulated by Interleukin (IL)-13 and Interferon γ and Inhibits Tumor Necrosis Factor α–induced IL-8 Release , 1998, The Journal of experimental medicine.

[8]  C. Mackay,et al.  Human Eotaxin Induces α4 and β2 Integrin-Dependent Eosinophil Accumulation in Rat Skin In Vivo: Delayed Generation of Eotaxin in Response to IL-4 , 1998, The Journal of Immunology.

[9]  C. Clish,et al.  Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. , 1998, The Journal of clinical investigation.

[10]  A. Luster,et al.  Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation , 1997, Journal of leukocyte biology.

[11]  T. Takano,et al.  Aspirin-triggered 15-Epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-inflammatory Receptors , 1997, The Journal of experimental medicine.

[12]  C. Serhan.  Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? , 1997, Prostaglandins.

[13]  J. Drazen,et al.  Agonist-induced lipoxin A4 generation in vitro and in aspirin-sensitive asthmatics: detection by a novel lipoxin A4-ELISA. , 1997, Advances in experimental medicine and biology.

[14]  P. Weller.  Human eosinophils. , 1997, The Journal of allergy and clinical immunology.

[15]  V. Lagente,et al.  Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. , 1996, European journal of pharmacology.

[16]  M. Martins,et al.  Alloxan diabetes reduces pleural mast cell numbers and the subsequent eosinophil influx induced by allergen in sensitized rats. , 1996, International Archives of Allergy and Immunology.

[17]  O. D. Wolthers.  Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids. , 1996, The European respiratory journal.

[18]  C. Serhan,et al.  Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. , 1996, Journal of immunology.

[19]  I. Akritopoulou‐Zanze,et al.  Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. , 1995, Biochemistry.

[20]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[21]  B. Spur,et al.  Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet‐activating factor and N‐formyl‐L‐methionyl‐L‐leucyl‐L‐phenylalanine , 1994, Allergy.

[22]  C. Serhan,et al.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. , 1993, The Journal of clinical investigation.

[23]  G. Gleich,et al.  The biology of the eosinophilic leukocyte. , 1993, Annual review of medicine.

[24]  M. Martins,et al.  Pharmacological modulation of the late eosinophilia induced by antigen in actively sensitized rats. , 1992, International archives of allergy and immunology.

[25]  B. Spur,et al.  The effects of lipoxin A4 on airway responses in asthmatic subjects. , 1992, The American review of respiratory disease.

[26]  C. Sanderson,et al.  Interleukin-5, eosinophils, and disease. , 1992, Blood.

[27]  J. Lindgren,et al.  Lipoxin formation in human nasal polyps and bronchial tissue , 1990, FEBS letters.

[28]  V. Gant,et al.  Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. , 1990, The American review of respiratory disease.

[29]  B. Spur,et al.  Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. , 1989, Clinical science.

[30]  B. Vargaftig,et al.  Pharmacological modulation of Paf‐induced rat pleurisy and its role in inflammation by zymosan , 1989, British journal of pharmacology.

[31]  M. Martins,et al.  Late eosinophil mobilization induced by PAF-acether in the pleural cavity of rats. , 1989, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[32]  J. Palmblad,et al.  Formation of lipoxin A by granulocytes from eosinophilic donors , 1987, FEBS letters.

[33]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[34]  A. Gornall,et al.  Determination of serum proteins by means of the biuret reaction. , 1949, The Journal of biological chemistry.